Pfizer in deal with Australian drug delivery product firm

Share this article:
Pfizer and Australian bio-nanotech company Psivida have entered into an exclusive worldwide collaborative research and license agreement deal. Psivida, which develops drug delivery products primarily for ophthalmology and oncology, will receive up to $155 million in development and sales-related milestone payments, according to published reports. Additionally, Pfizer will invest $5 million in shares of Psivida upon entering the deal and $5 million in the future. The companies will develop ophthalmic products using Psivida’s technology, with Pfizer paying the cost of the joint-research program. Under the agreement, Pfizer will have exclusive license to market all the ophthalmic products developed under the collaboration and will pay a royalty on net sales of those products. Technology included under the collaboration includes Psivida’s Medidur, a small injectible device made for sustained release of drugs and being studied as a treatment for diabetic macular edema, a complication of diabetic retinopathy caused by fluid build-up in the central vision portion of the retina. Meanwhile, Caliper Life Sciences, a Massachusetts-based maker of reagents, software and screening systems for drug makers, said it will conduct profiling experiments on live animals for Pfizer. The one-year contract involves Caliper using its technology to study the effects of acute or chronic drug dosing in mice to find new uses for drugs already under development. Financial terms of the deal were not disclosed.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.